-
公开(公告)号：US20140080886A1
公开(公告)日：2014-03-20
申请号：US14029333
申请日：2013-09-17
Applicant: AbbVie Inc.
Inventor： Tami J. Pilot-Matias , Preethi Krishnan , Warren M. Kati , Christine A. Collins , Neeta C. Mistry , Clarence J. Maring , David A. DeGoey , John K. Pratt , Dachun Liu , Rolf Wagner
IPC: A61K31/4025 , A61K45/06
CPC classification number: A61K31/4025 , A61K31/401 , A61K45/06 , A61K2300/00
Abstract: Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.
-
公开(公告)号：US20170157104A1
公开(公告)日：2017-06-08
申请号：US15431069
申请日：2017-02-13
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: A61K31/454 , A61K31/4184 , A61K31/4439 , A61K31/422 , A61K31/438 , A61K31/4178 , A61K31/695 , A61K31/496 , A61K31/506 , A61K31/4418 , A61K31/5377 , A61K31/4355 , A61K45/06 , A61K31/4545
CPC classification number: A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US09428514B2
公开(公告)日：2016-08-30
申请号：US14564352
申请日：2014-12-09
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Warren M. Kati , Keith F. McDaniel , Chang H. Park , George S. Sheppard , Le Wang
IPC: A01N43/54 , C07D487/04 , C07D211/86 , C07D405/04 , C07D401/04 , C07D417/04 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D213/69
CPC classification number: A61K31/506 , A61K31/4412 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/497 , C07D211/86 , C07D213/69 , C07D401/04 , C07D401/12 , C07D405/04 , C07D405/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D487/04
Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
Abstract translation: 本发明提供式（I）化合物，其中Y1，Y2，R1，R2，R3，A1，A2，A3和A4具有说明书中定义的任何值及其药学上可接受的盐，其是有用的 作为治疗疾病和病症的药剂，包括炎性疾病，癌症和艾滋病。 还提供了由一种或多种式（I）化合物组成的药物组合物。
-
公开(公告)号：US20150158873A1
公开(公告)日：2015-06-11
申请号：US14564352
申请日：2014-12-09
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Warren M. Kati , Keith F. McDaniel , Chang H. Park , George S. Sheppard , Le Wang
IPC: C07D487/04 , C07D417/04 , C07D401/04 , C07D211/86 , C07D405/04
CPC classification number: A61K31/506 , A61K31/4412 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/497 , C07D211/86 , C07D213/69 , C07D401/04 , C07D401/12 , C07D405/04 , C07D405/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D487/04
Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
Abstract translation: 本发明提供式（I）化合物，其中Y1，Y2，R1，R2，R3，A1，A2，A3和A4具有说明书中定义的任何值及其药学上可接受的盐，其是有用的 作为治疗疾病和病症的药剂，包括炎性疾病，癌症和艾滋病。 还提供了由一种或多种式（I）化合物组成的药物组合物。
-
公开(公告)号：US20250152600A1
公开(公告)日：2025-05-15
申请号：US18742823
申请日：2024-06-13
Applicant: AbbVie Inc.
Inventor： Le Wang , John K. Pratt , Keith F. McDaniel , Steven D. Fidanze , Lisa Hasvold , James H. Holms , Warren M. Kati , Dachun Liu , Robert A. Mantei , William J. McClellan , George S. Sheppard , Carol K. Wada , Yujia Dai
IPC: A61K31/541 , A61K31/437 , A61K31/5025 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
-
Patent Agency Ranking
公开(公告)号：US20230285378A1
公开(公告)日：2023-09-14
申请号：US17941090
申请日：2022-09-09
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Warren M. Kati , Tammie K. Jinkerson , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: A61K31/454 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07D403/14 , C07F7/02 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , A61K31/435
CPC classification number: A61K31/454 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07D403/14 , C07F7/02 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , A61K31/435 , Y02P20/582
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US20190008866A1
公开(公告)日：2019-01-10
申请号：US16117203
申请日：2018-08-30
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Warren M. Kati , Keith F. McDaniel , Chang H. Park , George S. Sheppard , Le Wang
IPC: A61K31/506 , C07D487/04 , A61K31/4412 , A61K31/4433 , A61K31/4439 , A61K31/4709 , A61K31/497 , C07D211/86 , C07D213/69 , C07D401/04 , C07D401/12 , C07D405/04 , C07D405/12 , C07D413/12 , C07D417/04 , A61K31/444 , C07D417/12
Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
公开(公告)号：US20180296566A1
公开(公告)日：2018-10-18
申请号：US16012379
申请日：2018-06-19
Applicant: AbbVie Inc.
Inventor： Le Wang , John K. Pratt , Keith F. McDaniel , Yujia Dai , Steven D. Fidanze , Lisa Hasvold , James H. Holms , Warren M. Kati , Dachun Liu , Robert A. Mantei , William J. McClellan , George S. Sheppard , Carol K. Wada
IPC: A61K31/541 , A61K45/06 , C07D487/04 , C07D471/04 , A61K31/5025 , A61K31/437 , A61K31/5377
Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
-
公开(公告)号：US10085985B2
公开(公告)日：2018-10-02
申请号：US15216855
申请日：2016-07-22
Applicant: AbbVie Inc.
Inventor： Andrew Bogdan , Warren M. Kati , Keith F. McDaniel , Chang H. Park , George S. Sheppard , Le Wang
IPC: A61K31/506 , C07D487/04 , C07D211/86 , C07D405/04 , C07D401/04 , C07D417/04 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D213/69 , A61K31/4412 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/497
Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
公开(公告)号：US20170157105A1
公开(公告)日：2017-06-08
申请号：US15434789
申请日：2017-02-16
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: A61K31/695
CPC classification number: A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.049 seconds)
